サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1565676

カポジ肉腫市場：製品タイプ別、治療別、診断別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測

Kaposi Sarcoma Market, By Product Type, By Treatment, By Diagnostic, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 288 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
カポジ肉腫市場：製品タイプ別、治療別、診断別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年09月04日
発行: AnalystView Market Insights
ページ情報: 英文 288 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

カポジ肉腫の市場規模は2023年に1億4,030万米ドルとなり、2024年から2032年にかけてCAGR 4.90％で拡大

カポジ肉腫市場-市場力学

HIV関連カポジ肉腫の革新的治療が市場成長を後押し

HIV関連カポジ肉腫（KS）に対する革新的な治療法は、患者の予後を改善し、標的治療に対する需要を増加させることで、市場の成長を促進しています。抗レトロウイルス療法とKSに特化した治療の進歩は、生活の質と生存率を高め、この分野への投資と開発を促しています。2022年、米国がん学会が発表した研究。この研究では、HIV関連カポジ肉腫に対する新規治療法のイントロダクションより、同疾患の年間罹患率が大幅に低下していることが明らかになった。具体的には、HIV陽性者におけるカポジ肉腫の発症率は2010年から2022年にかけて約40％減少しており、これは抗レトロウイルス療法と標的治療の進歩によるところが大きいです。

カポジ肉腫市場-主要インサイト

調査アナリストの分析によると、世界市場は予測期間（2024-2032年）に約4.90%のCAGRで毎年成長すると推定されます。

製品タイプ別では、流行性（AIDS関連）カポジ肉腫が2023年に最大の市場シェアを示すと予測されます。

治療セグメンテーションに基づくと、2023年にはHAART（Highly Active Antiretroviral Therapy：高活性抗レトロウイルス療法）が主要タイプでした。

診断セグメンテーションに基づくと、2023年には生検が主要タイプでした。

地域別では、北米が2023年に収益でリードしました。

カポジ肉腫市場-セグメンテーション分析：

世界のカポジ肉腫市場は、製品タイプ、治療、診断、エンドユーザー、地域に基づいてセグメント化されます。

市場は製品タイプに基づいて3つに分類される：流行性（AIDS関連）カポジ肉腫、古典的（地中海型）カポジ肉腫、風土病性（アフリカ型）カポジ肉腫、異所性（移植関連）カポジ肉腫です。カポジ肉腫市場で最も顕著なセグメントは、流行性（AIDS関連）カポジ肉腫です。この病型は、カポジ肉腫を発症する主な危険因子であるHIV/AIDSの高い蔓延により、最も重要なものとなっています。世界のAIDSの流行が続く中、このタイプのカポジ肉腫は依然として重大な関心事であり、的を絞った治療と研究の需要を牽引しています。他の病型は重要ではあるが、流行病型の有病率や影響力には及ばないです。

市場は治療法に基づき6つのカテゴリーに分類される：高活性抗レトロウイルス療法（HAART）、放射線療法、外科手術、凍結手術、化学療法、生物学的療法です。カポジ肉腫市場で最も顕著な治療セグメントはHAART（Highly Active Antiretroviral Therapy）です。HAARTは、カポジ肉腫の主要な危険因子であるHIV/AIDS感染に対処する点で重要です。HAARTによるHIVの効果的な管理は、ウイルスを制御し、関連合併症の有病率を低下させることにより、カポジ肉腫の転帰の大幅な改善につながります。放射線療法、外科手術、化学療法などの他の治療法も重要であるが、HAARTはAIDS関連カポジ肉腫の根本原因を管理する役割を担っているため、HAARTが支配的なアプローチとなっています。

カポジ肉腫市場-地理的洞察

北米のカポジ肉腫（KS）治療市場は、いくつかの重要な要因の影響を受けています。主にHIV/AIDSに関連するKSの流行は市場力学に影響を与え、米国とカナダで症例の大半が見られます。抗レトロウイルス療法（ART）の進歩によりKSの治療成績は改善し、特定のKS治療に対する市場の需要は減少しています。しかし、進行中の症例や再発のため、効果的な治療法の必要性は続いています。標的治療薬の研究開発と臨床試験が市場の成長に寄与しています。大手製薬企業や研究機関の存在が、新たな治療法の開発を後押ししています。規制の枠組み、ヘルスケア政策、ヘルスケアサービスへのアクセスも市場情勢の形成に重要な役割を果たしています。全体として、市場はニッチではあるが、継続的な技術革新と患者の転帰の改善に注力することで支えられています。

カポジ肉腫市場-競合情勢：

カポジ肉腫市場を牽引するのは、HIV/AIDS治療や腫瘍治療に深く関わるギリアド・サイエンシズ、ブリストル・マイヤーズスクイブ、メルク社、ファイザー社などの主要企業です。その他、ノバルティスAG、ロシュ・ホールディングAG、イーライリリーなどの注目すべき企業が、がん研究を通じて貢献しています。市場力学としては、抗ウイルス療法、標的療法、免疫療法に重点が置かれ、研究開発に多額の投資が行われています。規制上の課題とカポジ肉腫の希少性が市場成長に影響を与えています。個別化療法と併用療法に機会があります。競合情勢は、現在進行中の技術革新と治療戦略の進歩によって形成されています。

目次

第1章 カポジ肉腫市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 カポジ肉腫の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 カポジ肉腫産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 カポジ肉腫市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 カポジ肉腫の市場情勢

  • カポジ肉腫市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 カポジ肉腫市場- 製品タイプ別

  • 概要
    • セグメントシェア分析
    • 流行性（エイズ関連）カポジ肉腫
    • 古典的（地中海型）カポジ肉腫
    • 風土病性（アフリカ）カポジ肉腫
    • 医原性（移植関連）カポジ肉腫

第8章 カポジ肉腫市場- 治療別

  • 概要
    • セグメントシェア分析
    • 高活性抗レトロウイルス療法（HAART）
    • 放射線治療
    • 手術
    • 凍結療法
    • 化学療法
    • 生物学的療法

第9章 カポジ肉腫市場- 診断別

  • 概要
    • セグメントシェア分析
    • 気管支鏡検査
    • 消化管内視鏡検査
    • 生検
    • その他

第10章 カポジ肉腫市場- エンドユーザー別

  • 概要
    • セグメントシェア分析
    • 病院
    • 在宅ケア
    • その他

第11章 カポジ肉腫市場- 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析- カポジ肉腫業界

  • 競争ダッシュボード
  • 企業プロファイル
    • Gilead Sciences
    • Bristol-Myers Squibb
    • Merck &Co.
    • Pfizer Inc.
    • Novartis AG
    • Roche Holding AG
    • Eli Lilly and Company
    • Amgen Inc.
    • Celgene Corporation（now part of Bristol-Myers Squibb）
    • AbbVie Inc.
    • Johnson &Johnson
    • Regeneron Pharmaceuticals
    • Incyte Corporation
    • Sandoz（a Novartis division）
    • Alimera Sciences

第13章 アナリストの全方位展望

目次
Product Code: ANV3886

REPORT HIGHLIGHT

Kaposi Sarcoma Market size was valued at USD 140.30 million in 2023, expanding at a CAGR of 4.90% from 2024 to 2032.

Kaposi sarcoma (KS) is a rare and often aggressive cancer that originates from the cells lining blood vessels and lymphatic vessels. It is characterized by the development of abnormal growths or tumors on the skin, in the mouth, or internal organs. KS is most commonly associated with human herpesvirus 8 (HHV-8) infection and is frequently seen in individuals with weakened immune systems, such as those with HIV/AIDS. The market for Kaposi sarcoma treatments includes pharmaceuticals, such as antiretroviral drugs and chemotherapy agents, as well as targeted therapies and immunotherapies. The market dynamics are influenced by factors such as disease prevalence, advancements in treatment, and the availability of innovative therapies.

Kaposi Sarcoma Market- Market Dynamics

Innovative treatments for HIV-related Kaposi Sarcoma boosting market growth.

Innovative treatments for HIV-related Kaposi Sarcoma (KS) are driving growth in the market by improving patient outcomes and increasing demand for targeted therapies. Advances in antiretroviral therapies and KS-specific treatments enhance the quality of life and survival rates, prompting greater investment and development in this sector. 2022 study published by the American Cancer Society. The study revealed that the introduction of novel therapies for HIV-related Kaposi Sarcoma has led to a significant decline in the annual incidence rate of the disease. Specifically, the incidence of Kaposi Sarcoma among HIV-positive individuals decreased by approximately 40% from 2010 to 2022, attributed largely to advancements in antiretroviral therapies and targeted treatments.

Kaposi Sarcoma Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.90% over the forecast period (2024-2032)

Based on product type segmentation, Epidemic (AIDS Associated) Kaposi Sarcoma was predicted to show maximum market share in the year 2023

Based on Treatment segmentation, is Highly Active Antiretroviral Therapy (HAART) was the leading type in 2023

Based on Diagnostic segmentation, Biopsy was the leading type in 2023

based on region, North America was the leading revenue generator in 2023

Kaposi Sarcoma Market- Segmentation Analysis:

The Global Kaposi Sarcoma Market is segmented on the basis of Product Type, Treatment, Diagnostic, End User, and Region.

The market is divided into three categories based on product type: Epidemic (AIDS Associated) Kaposi Sarcoma, Classic (Mediterranean) Kaposi Sarcoma, Endemic (African) Kaposi Sarcoma, Iatrogenic (Transplant-Related) Kaposi Sarcoma. The most prominent segment in the Kaposi Sarcoma market is the Epidemic (AIDS Associated) Kaposi Sarcoma. This form of the disease has become the most significant due to the high prevalence of HIV/AIDS, which is a major risk factor for developing Kaposi Sarcoma. With the ongoing global AIDS epidemic, this type of Kaposi Sarcoma remains a critical concern, driving the demand for targeted treatments and research. The other types, while important, do not match the prevalence and impact of the epidemic variant.

The market is divided into six categories based on Treatment: Highly Active Antiretroviral Therapy (HAART), Radiation Therapy, Surgery, Cryosurgery, Chemotherapy, Biological Therapy. The most prominent treatment segment in the Kaposi Sarcoma market is Highly Active Antiretroviral Therapy (HAART). HAART is significant because it addresses the underlying HIV/AIDS infection, which is a major risk factor for Kaposi Sarcoma. Effective management of HIV through HAART can lead to significant improvements in Kaposi Sarcoma outcomes by controlling the virus and reducing the prevalence of related complications. While other treatments like Radiation Therapy, Surgery, and Chemotherapy are also important, HAART's role in managing the root cause of AIDS-associated Kaposi Sarcoma makes it the dominant approach.

Kaposi Sarcoma Market- Geographical Insights

The North American market for Kaposi's sarcoma (KS) treatment is influenced by several key factors. The prevalence of KS, primarily linked to HIV/AIDS, impacts market dynamics, with the majority of cases seen in the U.S. and Canada. Advances in antiretroviral therapy (ART) have improved KS outcomes, reducing the market demand for specific KS treatments. However, the need for effective therapies continues due to ongoing cases and relapses. Research and development in targeted therapies and clinical trials are contributing to market growth. The presence of major pharmaceutical companies and research institutions enhances the development of new treatments. Regulatory frameworks, healthcare policies, and access to healthcare services also play a crucial role in shaping the market landscape. Overall, while the market is niche, it is supported by continuous innovation and a focus on improving patient outcomes.

Kaposi Sarcoma Market- Competitive Landscape:

The Kaposi sarcoma market is driven by key players including Gilead Sciences, Bristol-Myers Squibb, Merck & Co., and Pfizer Inc., who are deeply involved in HIV/AIDS and oncology therapies. Other notable companies like Novartis AG, Roche Holding AG, and Eli Lilly contribute through their oncology research. Market dynamics include a focus on antiviral, targeted, and immunotherapies, with significant investments in R&D. Regulatory challenges and the rare nature of Kaposi sarcoma impact market growth. Opportunities lie in personalized and combination therapies. The competitive landscape is shaped by ongoing innovations and advancements in treatment strategies.

Recent Developments:

In July 2024, The USFDA approved ForDoz's injection, which contains doxorubicin hydrochloride in liposome form, for use in treating certain cancers. This formulation aims to improve the drug's delivery and reduce side effects compared to traditional doxorubicin..

In February 2023, Researchers at the University of North Carolina School of Medicine have discovered a protein that helps the Epstein-Barr virus (EBV) and the Kaposi sarcoma-associated herpesvirus (KSHV) cause disease and spread.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL KAPOSI SARCOMA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Gilead Sciences
  • Bristol-Myers Squibb
  • Merck & Co.
  • Pfizer Inc.
  • Novartis AG
  • Roche Holding AG
  • Eli Lilly and Company
  • Amgen Inc.
  • Celgene Corporation (now part of Bristol-Myers Squibb)
  • AbbVie Inc.
  • Johnson & Johnson
  • Regeneron Pharmaceuticals
  • Incyte Corporation
  • Sandoz (a Novartis division)
  • Alimera Sciences

GLOBAL KAPOSI SARCOMA MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Epidemic (AIDS Associated) Kaposi Sarcoma
  • Classic (Mediterranean) Kaposi Sarcoma
  • Endemic (African) Kaposi Sarcoma
  • Iatrogenic (Transplant-Related) Kaposi Sarcoma

GLOBAL KAPOSI SARCOMA MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Highly Active Antiretroviral Therapy (HAART)
  • Radiation Therapy
  • Surgery
  • Cryosurgery
  • Chemotherapy
  • Biological Therapy

GLOBAL KAPOSI SARCOMA MARKET, BY DIAGNOSTIC- MARKET ANALYSIS, 2019 - 2032

  • Bronchoscopy
  • Gastrointestinal Endoscopy
  • Biopsy
  • Others

GLOBAL KAPOSI SARCOMA MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Homecare
  • Others

GLOBAL KAPOSI SARCOMA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Kaposi sarcoma Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Kaposi sarcoma Market Snippet by Product Type
    • 2.1.2. Kaposi sarcoma Market Snippet by Treatment
    • 2.1.3. Kaposi sarcoma Market Snippet by Diagnostic
    • 2.1.4. Kaposi sarcoma Market Snippet by End User
    • 2.1.5. Kaposi sarcoma Market Snippet by Country
    • 2.1.6. Kaposi sarcoma Market Snippet by Region
  • 2.2. Competitive Insights

3. Kaposi sarcoma Key Market Trends

  • 3.1. Kaposi sarcoma Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Kaposi sarcoma Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Kaposi sarcoma Market Opportunities
  • 3.4. Kaposi sarcoma Market Future Trends

4. Kaposi sarcoma Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Kaposi sarcoma Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Kaposi sarcoma Market Landscape

  • 6.1. Kaposi sarcoma Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Kaposi sarcoma Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2023 & 2032 (%)
    • 7.1.2. Epidemic (AIDS Associated) Kaposi Sarcoma
    • 7.1.3. Classic (Mediterranean) Kaposi Sarcoma
    • 7.1.4. Endemic (African) Kaposi Sarcoma
    • 7.1.5. Iatrogenic (Transplant-Related) Kaposi Sarcoma

8. Kaposi sarcoma Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2023 & 2032 (%)
    • 8.1.2. Highly Active Antiretroviral Therapy (HAART)
    • 8.1.3. Radiation Therapy
    • 8.1.4. Surgery
    • 8.1.5. Cryosurgery
    • 8.1.6. Chemotherapy
    • 8.1.7. Biological Therapy

9. Kaposi sarcoma Market - By Diagnostic

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Diagnostic, 2023 & 2032 (%)
    • 9.1.2. Bronchoscopy
    • 9.1.3. Gastrointestinal Endoscopy
    • 9.1.4. Biopsy
    • 9.1.5. Others

10. Kaposi sarcoma Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Treatment, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Homecare
    • 10.1.4. Others

11. Kaposi sarcoma Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Kaposi sarcoma Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Kaposi sarcoma Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Kaposi sarcoma Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Kaposi sarcoma Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Kaposi sarcoma Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Kaposi sarcoma Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Gilead Sciences
    • 12.2.2. Bristol-Myers Squibb
    • 12.2.3. Merck & Co.
    • 12.2.4. Pfizer Inc.
    • 12.2.5. Novartis AG
    • 12.2.6. Roche Holding AG
    • 12.2.7. Eli Lilly and Company
    • 12.2.8. Amgen Inc.
    • 12.2.9. Celgene Corporation (now part of Bristol-Myers Squibb)
    • 12.2.10. AbbVie Inc.
    • 12.2.11. Johnson & Johnson
    • 12.2.12. Regeneron Pharmaceuticals
    • 12.2.13. Incyte Corporation
    • 12.2.14. Sandoz (a Novartis division)
    • 12.2.15. Alimera Sciences

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us